Cannabidiol has been praised for the many benefits it can deliver for health from reduced anxiety to the treatment of epilepsy. And while state laws have given their thumbs up to the substance, federal authorities are not too sure. CBD can be taken in a number of ways. The hemp-driven drug comes in the form of tinctures, vapors, capsules as well as treats ranging from cookies to coffee.
On Friday, the Food and Drug Administration had held it’s first ever hearing on the trending marijuana component – cannabidiol. The hearing was conducted so that the FDA could conclude how CBD must be regulated in edibles and drinkables. Unfortunately, we don’t have a solid answer yet.
This is because there was a lot of confusion that resulted even though this hearing was carried out to clear exactly that. The issue is this – FDA wants people and experts to weigh in on whether or not cannabidiol can be trusted. Does the substance cause one to become high?
Various studies have pointed out that it is not CBD that leads to psychoactive symptoms on being ingested – that con is associated to THC which happens to come from the same plant that CBD comes from. The topic of FDA’s hearing was so hot that 400 applicants lined up for testifying. Unfortunately, of these only 120 actually did.
Some of these people spoke against CBD, certainly due to their lack of knowledge as it is THC that is evil not cannabidiol. Sure, CBD does induce calm. But this doesn’t mean that it makes users high. Leafly, which happens to be the most reliable source of cannabis-related information, pointed out as well that this hearing exhibited confusion.
Leafly also mentioned another takeaway from Friday’s hearing – it said that a big problem related to the cannabis market right now are products that are not good enough. Ever since state governments have legalized CBD, several products have jumped to market shelves.
Unfortunately, not all of these are worth trusting. Several advertise fake claims. They claim they contain a higher amount of CBD than they truthfully do. This shows that one thing the FDA would be doing is putting into place quality requirements to ensure low standard products are limited.
Other takeaways as discussed by Leafly also included that the FDA has concerns for any negative side effects associated with cannabidiol use. Since the FDA only values scientific evidence, personal stories cannot sway its decisions one way or another.
During the opening of the hearing, FDA’s Acting Commissioner Ned Sharpless, M.D., said, “critical questions remain about the safety. While we have seen an explosion of interest in products containing CBD, there is still much that we don’t know.” The market is waiting for FDA’s final response on the matter.
If it approves use, the industry will only grow. However, it is necessary for people to be able to differentiate between bad CBD products that make fake claims and actually good ones from reputable companies.